任何部位局限性血管肉瘤患者的化疗:一项欧洲回顾性研究
该回顾性研究纳入2005年1月至2019年12月间33个欧洲肉瘤参考中心接受根治性手术的362例原发性局限性血管肉瘤患者,比较接受与未接受(新)辅助化疗者的总生存(OS)、无病生存(DFS)和远处转移无生存(DMFS)。倾向评分匹配后OS、DFS、DMFS的HR均未达统计学显著;亚组分析提示肿瘤≥50 mm或10年死亡风险较高的患者可能从化疗中获益。
要点
- 362例原发性局限性血管肉瘤患者中,149例(41.2%)接受(新)辅助化疗,213例(58.6%)未接受。
- 倾向评分匹配分析中OS的HR为0.74(95%CI 0.38-1.43;p=0.367),未达统计学显著。
- 肿瘤小于50 mm或死亡风险较低的患者似乎不能从化疗中获益,而肿瘤较大或10年死亡风险较高的患者似乎获益明显。
核心结论
- 这项大型回顾性研究提示,肿瘤大于50 mm和/或高风险的Primary、局限性血管肉瘤患者可能从(新)辅助化疗中获益。
研究设计与样本
- 回顾性研究,纳入2005年1月至2019年12月在33个欧洲肉瘤参考中心接受根治性手术的原发性局限性血管肉瘤患者,共分析362例。
- 主要目标为比较接受与未接受(新)辅助化疗患者的OS、DFS和DMFS,并采用倾向评分匹配(PSM)降低混杂风险。
- 亚组分析按肿瘤部位、肿瘤大小(<50 mm或≥50 mm)及根据Sarculator列线图预测的10年OS进行分层,采用≤33%或>33%以及<60%或≥60%两个不同截断值。
主要发现
- 149例(41.2%)接受(新)辅助化疗(治疗组),213例(58.6%)未接受(对照组)。
- OS终点中位随访时间为5.1年(95%CI 4.0-5.5)。
- 单因素分析中OS的HR为0.58(95%CI 0.40-0.83;p=0.003),PSM分析中OS的HR为0.74(95%CI 0.38-1.43;p=0.367)。
- 单因素分析中DFS的HR为0.75(95%CI 0.57-0.98;p=0.036),PSM分析中DFS的HR为0.91(95%CI 0.56-1.48;p=0.7)。
- 单因素分析中DMFS的HR为0.75(95%CI 0.55-1.02;p=0.065),PSM分析中DMFS的HR为0.92(95%CI 0.53-1.61;p=0.769)。
临床怎么用
- 原文结论提示,肿瘤大于50 mm和/或高风险的Primary、局限性血管肉瘤患者可能从(新)辅助化疗中获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We retrospectively investigated the role of (neo)adjuvant chemotherapy in patients with primary, localized angiosarcoma. METHODS: We selected all patients with primary, localized angiosarcoma, who had received radical surgery between January 2005 and December 2019 at 33 European sarcoma reference centers. The primary objective was to compare the outcome of patients who received (neo)adjuvant chemotherapy versus those who did not, in terms of overall survival (OS), disease-free survival (DFS) and distant metastasis-free survival (DMFS). To reduce the risk of confounding due to imbalance, a propensity-score matching(PSM) was performed. Finally, subgroups analysis was performed according to tumor site, tumor size (< 50 mm or ≥ 50 mm) and patients predicted 10-years OS according to the nomogram sarculator (two different cutoff-values were applied: ≤ 33% or > 33% and < 60% or ≥ 60%). RESULTS: 362 patients were analyzed: 149 (41.2%; treated group) received (neo) adjuvant chemotherapy and 213 (58.6%; control group) did not. The median follow-up for the OS endpoint was 5.1 years (95% CI: 4.0-5.5). The OS-HR was 0.58 (95%CI: 0.40-0.83; p-value = 0.003) in the univariate analysis and 0.74 (95% CI: 0.38-1.43; p = 0.367) in the PSM analysis. The DFS-HR was 0.75 (95% CI: 0.57-0.98; p-value = 0.036) in the univariate analysis, and 0.91 (95% CI:0.56-1.48; p-value = 0.7) in the PSM analysis. The DMFS-HR was 0.75 (95% CI: 0.55-1.02; p-value = 0.065) in univariate analysis and 0.92 (95% CI: 0.53-1.61; p-value = 0.769) in the PSM analysis. Subgroup analysis revealed no heterogeneity of results in strata of tumor site. On the contrary, there was a trend for heterogeneity according to tumor size and patient's risk of death. For all the endpoints analyzed, patients with tumors smaller than 50 mm or at lower risk of death seem to have no benefit from chemotherapy, while patients with larger tumors or at higher risk of death at 10 years seem to derive substantial benefit. CONCLUSION: This large, retrospective study suggests that patients affected by > 50 mm and/or high-risk primary, localized angiosarcoma could benefit from (neo)adjuvant chemotherapy.
引用
- Conforti F, Gronchi A, Penel N, et al. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. Eur J Cancer. 2022. PMID: 35728378. doi:10.1016/j.ejca.2022.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。